Effects of Remote Ischemic Preconditioning on Peripheral Blood Biomarkers in Healthy Adults (EMINENT)

Launched by FIRST AFFILIATED HOSPITAL XI'AN JIAOTONG UNIVERSITY · Jul 20, 2023

Keywords

ClinConnect Summary

The EMINENT clinical trial is investigating a technique called remote ischemic preconditioning, which may help protect the heart and blood vessels. In this study, researchers want to see how this technique affects the blood of healthy adults. The goal is to understand if it can reduce damage caused by a lack of blood flow and improve overall cardiovascular health.

To participate in this trial, you need to be between 18 and 45 years old and in good health. However, there are several conditions that would make you ineligible, such as having heart or blood vessel diseases, certain infections, or recent surgeries. If you join, you can expect to undergo some tests and procedures aimed at measuring how this technique influences your blood. It's important to know that you will need to sign a consent form agreeing to take part in this study.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Aged 18 to 45 years;
• • Be in good health;
• • Consent to participate in the clinical trial and sign the informed consent form.
• Exclusion Criteria:
• • Abnormal results in biochemical checks and physiological indicators.
• • Cardiovascular and cerebrovascular diseases: hypertension, coronary heart disease, congenital heart disease, cerebrovascular alterations, etc.
• • Endocrine diseases: diabetes, thyroid disorders, etc.
• • Hematologic diseases: anemia, paroxysmal hemoglobinuria, primary thrombocytosis, etc.
• • Infectious diseases: hepatitis B, hepatitis C, syphilis, etc.
• • Cancer.
• • Neurological and psychiatric disorders.
• • Vascular diseases: peripheral vascular disease, Raynaud's syndrome, thromboembolic diseases.
• • Major trauma or surgery within the last six months.
• • Pregnant or breastfeeding women.
• • Upper limbs unsuitable for compression treatment: history of upper limb surgery, presence of tissue damage and limb deformity, and concomitant hemorrhagic diseases.
• • Recent circumstances that may affect results: blood donors within the last month, any medication taken within the last month, fever within the last week, women within their menstrual cycle or within 7 days before the start of menstruation.
• • Patients who refuse to sign the informed consent form for participation in this study.